Clinical Benefit of Circulating Tumor DNA Analysis in Follow-up of Patients With Early-Stage Breast Cancer-Reply

Isaac Garcia-Murillas¹, Nicholas C Turner^{1

2}

Affiliations

¹ Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
² Breast Unit, Royal Marsden Hospital, London, United Kingdom.

Comment

Isaac Garcia-Murillas et al. JAMA Oncol. 2020.

. 2020 Mar 1;6(3):439-440.

doi: 10.1001/jamaoncol.2019.5682.

Isaac Garcia-Murillas¹, Nicholas C Turner^{1

2}

¹ Breast Cancer Now Research Centre, The Institute of Cancer Research, London, United Kingdom.
² Breast Unit, Royal Marsden Hospital, London, United Kingdom.

No abstract available

Comment on

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
Garcia-Murillas I, Chopra N, Comino-Méndez I, Beaney M, Tovey H, Cutts RJ, Swift C, Kriplani D, Afentakis M, Hrebien S, Walsh-Crestani G, Barry P, Johnston SRD, Ring A, Bliss J, Russell S, Evans A, Skene A, Wheatley D, Dowsett M, Smith IE, Turner NC. Garcia-Murillas I, et al. JAMA Oncol. 2019 Oct 1;5(10):1473-1478. doi: 10.1001/jamaoncol.2019.1838. JAMA Oncol. 2019. PMID: 31369045 Free PMC article.
Clinical Benefit of Circulating Tumor DNA Analysis in Early-Stage Breast Cancer.
Chitkara G, Hawaldar R, Badwe RA. Chitkara G, et al. JAMA Oncol. 2020 Mar 1;6(3):439. doi: 10.1001/jamaoncol.2019.5677. JAMA Oncol. 2020. PMID: 31855227 No abstract available.